Polar’s Fight: Week 1 Ignites Hope, Week 2 Progress Unfolds

Polar Inu’s journey presses forward with unwavering resolve. Our 10-year-old husky, Polar, confronts anal sac adenocarcinoma (ASAC)—observed in May 2024, diagnosed in June. Veterinary prognosis estimated 6-18 months without intervention; Polar has surpassed 10 months through a ketogenic diet initiated in June, press-pulse therapy since November, and Dr. William Makis’s protocol launched March 30, 2025, following a $500 Ethereum-funded consultation with 3 months of email follow-up. The regimen includes keto, fenbendazole, ivermectin (oral and 1.87% paste), and a veterinary paste (post-MDR1 clearance).

Week 1 delivered striking results: inflammation plummeted, tumors softened. Week 2 updates, including a progress photo before April 13, will offer week-to-week comparisons—early signs suggest further inflammation reduction. This documentation supports our community and informs Dr. Makis’s ongoing guidance.

Dr. Makis’s recent X post (@MakisMD, April 8) bolsters our optimism: a 7-year-old dog with lymphoma—facing an extreme tumor burden and no chemotherapy prospects—achieved rapid remission on his Ivermectin and Fenbendazole protocol. Lymphoma responds strongly, he notes. Could ASAC follow suit?

ASAC is rare and aggressive, with a 20-30% 5-year survival rate via surgery (which we’ve declined) and a 12-24-month median survival time (MST) if metastatic (50-90% risk at diagnosis, Vet Sci, 2020), likely present here due to multiple biopsies (MST ~219-548 days). Polar’s solid-type ASAC poses a formidable challenge. Yet, the protocol counters: keto restricts glucose, ivermectin and fenbendazole target growth pathways—week 1’s inflammation drop signals efficacy. Drawing from week 1, Makis’s lymphoma success, and his Stage 4 human remission rates (e.g., pancreatic cancer rising from 3% to 20-30%), odds stand at 50-60% for tumor reduction (subtle or substantial) and 40-50% for remission by June 29, 2025. These are informed estimates, not veterinary certainties, rooted in ASAC’s baseline (<10% remission without surgery, Vet Prac, 2022), lifted 3-10x by Makis’s approach, and tempered by metastasis—week 2’s photo will refine this outlook.

Polar powers Polar Inu ($POLAR, $5K cap, x.com/PolarInu_SOL). As its founder, I envision a $1.3M surge to be a conservative figure if victory arrives—a personal aspiration, not an investment directive. Conduct your own due diligence.

Week 1 sparked hope; week 2’s proof nears. Will Polar achieve tumor reduction or remission?

This is not veterinary advice—consult professionals.